Centre should intervene when patented medicines are sold at exorbitant rate: Kerala HC

Court holds that Central government can use a medicine’s patent to manufacture and sell it to public, including underprivileged patients, on non-commercial basis

Updated - September 28, 2026 12:36 pm IST - KOCHI

The petitioner had passed away while the plea was pending, and the court had then taken up the matter considering the larger public interest. | Photo Credit: The Hindu

The Kerala High Court on Monday (September 28, 2026) held that the Central government can use a medicine’s patent to manufacture and sell it to the public, including underprivileged patients, on a non-commercial basis.

Justice Harisankar V. Menon maintained that the Centre should invoke the relevant provisions under the Patents Act, 1970, where medicines manufactured on the basis of a patent are sold at an exorbitant price. The government should collate the data and decide whether a particular medicine was affordable and, if necessary, use the patent in the public interest and notify the patent holder.

“The government is required to provide all necessary facilities to citizens to ensure access to healthcare, including access to life-saving treatment, as in the case at hand,” the court held.

The petition was filed by a breast cancer patient. She had been prescribed Ribociclib for her condition, which, at the time, cost around ₹75,000 per month for her. The petition sought directions for the government to take over Ribociclib’s patent and make it available at the lowest price possible. The petitioner had passed away while the plea was pending, and the court had then taken up the matter considering the larger public interest.

Pharmaceutical firms oppose plea

Pharmaceutical companies had opposed the petition, stating that the Centre had already considered the matter of using Ribociclib’s patent but did not find it necessary, since a cheaper alternative, Palbociclib, was already available in the market.

Published - September 28, 2026 12:21 pm IST

Terms & conditions | Institutional Subscriber

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.